Affinage

SORCS3

VPS10 domain-containing receptor SorCS3 · UniProt Q9UPU3

Length
1222 aa
Mass
135.8 kDa
Annotated
2026-06-10
19 papers in source corpus 13 papers cited in narrative 13 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SORCS3 is a VPS10-domain type-I transmembrane sorting receptor that governs intracellular trafficking and synaptic receptor positioning in neurons (PMID:10600506, PMID:24069373). It is synthesized as a proprotein matured by N-terminal propeptide cleavage in the distal Golgi and binds neurotrophin ligand NGF through its extracellular VPS10 domain (PMID:15710408). Its cytoplasmic tail carries canonical endocytic motifs that target the receptor to the Golgi and vesicular compartments and drive AP-2-dependent internalization, localizing the receptor to somatic and dendritic vesicles in neurons (PMID:10600506, PMID:24715575). At the postsynaptic density SORCS3 functionally interacts with the adaptor PICK1 (and PSD-95) to control glutamate (AMPA) receptor trafficking; its loss abrogates long-term depression, mislocalizes PICK1, reduces basal synaptic transmission, and increases postsynaptic AMPA receptor mobility (PMID:24069373, PMID:27935149). More broadly, SORCS3 acts as a trafficking receptor that routes growth-factor and neurotrophin receptors—TrkB, p75NTR, and IGF2R—from endosomes toward lysosomal degradation, thereby attenuating BDNF, NGF/p75NTR, and PI3K/Akt and MAPK/Erk signaling, with consequences for energy homeostasis and tumor cell invasion and proliferation (PMID:29440124, PMID:35393432, PMID:41121295). Structurally, the extracellular region exists in a glycosylation-regulated equilibrium of monomers and homodimers, and cryo-EM resolves monomeric, M-shaped, and N-shaped conformations whose dimer geometry depends on PKD1-2 domain assembly (PMID:28827148, PMID:35940132).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1999 Medium

    Established SORCS3 as a distinct VPS10-domain receptor and predicted, from its domain architecture, that it could function in rapid internalization and signaling.

    Evidence Molecular cloning, sequence and domain analysis identifying VPS10 domain, leucine-rich repeats, transmembrane domain, and a short cytoplasmic tail with internalization and SH2/SH3 motifs

    PMID:10600506

    Open questions at the time
    • No functional mutagenesis of the predicted internalization or SH2/SH3 motifs
    • Ligands and trafficking behavior not yet tested
  2. 2000 Medium

    Revealed that alternative splicing can produce a SORCS3 isoform with an identical ectodomain but a divergent cytoplasmic tail lacking sorting signals, implying tail-dependent control of trafficking fate.

    Evidence RT-PCR and cDNA cloning of a splice variant

    PMID:10760602

    Open questions at the time
    • Functional consequences of the divergent tail not validated
    • Relative expression and tissue distribution of isoforms unknown
  3. 2004 Medium

    Linked SORCS3 to neuronal activity by showing its hippocampal expression is induced by seizure activity independently of new protein synthesis, distinguishing it from SorCS1.

    Evidence In situ hybridization in a kainic acid seizure model with protein synthesis inhibitor controls

    PMID:15009648

    Open questions at the time
    • Mechanism coupling activity to expression not defined
    • Functional role of induced receptor not tested
  4. 2005 High

    Defined SORCS3 maturation and its first ligand, showing it is processed by propeptide cleavage in the Golgi, resides predominantly at the plasma membrane, and binds NGF.

    Evidence Pulse-chase processing assay, purified-receptor ligand binding, and subcellular localization in transfected cells

    PMID:15710408

    Open questions at the time
    • Reported slow internalization conflicts with later AP-2-dependent endocytosis data
    • Physiological consequence of NGF binding not established
  5. 2013 High

    Placed SORCS3 at the postsynaptic density as a required regulator of long-term depression and glutamate receptor trafficking via PICK1.

    Evidence Knockout mice with LTD electrophysiology, PSD fractionation, targeted proteomics identifying PICK1, and fear extinction behavior

    PMID:24069373

    Open questions at the time
    • Direct biochemical mode of PICK1 interaction not resolved
    • AMPA receptor cargo handling inferred rather than directly tracked
  6. 2014 Medium

    Showed the cytoplasmic domain alone determines Golgi/vesicular targeting and drives AP-2-dependent endocytosis, assigning the trafficking determinants to the receptor tail.

    Evidence Chimeric receptor expression, AP-2 co-localization, and endocytic motif analysis in neurons

    PMID:24715575

    Open questions at the time
    • Single lab; specific motif residues not exhaustively mapped
    • Reconciliation with earlier slow-internalization observation incomplete
  7. 2017 High

    Connected SORCS3 loss to defective synaptic dynamics, showing reduced basal transmission, enhanced facilitation, and impaired depression consistent with increased postsynaptic AMPA receptor mobility, and reinforced PSD-95/PICK1 association.

    Evidence Patch-clamp and field recordings on knockout brain slices with multiple stimulation protocols, plus immunohistochemistry

    PMID:27935149

    Open questions at the time
    • AMPA receptor mobility inferred from physiology, not directly imaged
    • Quantitative receptor stoichiometry at the PSD not established
  8. 2017 High

    Established that the SORCS3 ectodomain self-associates and that glycosylation tunes the monomer-dimer equilibrium, introducing oligomeric state as a regulatory layer.

    Evidence Purified-protein electron microscopy, reciprocal Co-IP from membranes, and enzymatic deglycosylation

    PMID:28827148

    Open questions at the time
    • Functional consequence of dimerization for ligand sorting unresolved
    • In vivo regulation of glycosylation state unknown
  9. 2018 Medium

    Demonstrated SORCS3 (with SORCS1) functions as an intracellular trafficking receptor for TrkB to attenuate BDNF signaling, linking the receptor to energy homeostasis.

    Evidence Single and dual knockout mice, biochemical trafficking assays, neuropeptide and metabolic phenotyping

    PMID:29440124

    Open questions at the time
    • SORCS3-specific contribution not fully separated from SORCS1
    • Direct TrkB binding interface not mapped
  10. 2022 Medium

    Extended the trafficking-receptor model to p75NTR, showing SORCS3 routes it to lysosomes to suppress NGF/p75NTR signaling and glioma invasion.

    Evidence Reciprocal Co-IP, immunofluorescence co-localization, lysosomal trafficking and degradation assays, and invasion/proliferation assays with knockdown/overexpression in GBM cells

    PMID:35393432

    Open questions at the time
    • Single lab and single tumor context
    • Whether interaction is direct via the VPS10 domain not defined
  11. 2022 High

    Provided atomic structures of full-length SORCS3, resolving monomeric and two distinct dimeric conformations and nominating residues for dimerization and polypeptide binding.

    Evidence Cryo-EM structure determination of full-length human SorCS3

    PMID:35940132

    Open questions at the time
    • Mutagenesis validation of the nominated residues not described
    • Functional state of each conformation in cells unknown
  12. 2025 Medium

    Generalized the endocytic, signaling-attenuating role to IGF2R, showing SORCS3 increases IGF2R levels and dampens PI3K/Akt and MAPK/Erk signaling in an endocytosis-dependent, tumor-suppressive manner.

    Evidence Co-IP, endosome co-localization, signaling western blots, and endocytosis-blockade rescue in adrenocortical carcinoma cells

    PMID:41121295

    Open questions at the time
    • Direct versus indirect IGF2R interaction unresolved
    • Single lab and single cancer context
  13. 2025 Medium

    Revealed a non-neuronal role in cell fate, where loss of SORCS3 in embryonic stem cells activates a totipotent-like state via Tfap2c and suppression of TGF-β, PI3K-AKT, and lysosome pathways.

    Evidence CRISPR knockout, single-cell transcriptomics, Tfap2c double-knockout epistasis, blastocyst-like assembly, and pathway inhibitor validation

    PMID:41178446

    Open questions at the time
    • Mechanistic link between SORCS3 trafficking and Tfap2c activation unclear
    • Direct cargo responsible for the fate change not identified

Open questions

Synthesis pass · forward-looking unresolved questions
  • How SORCS3 cargo selectivity is determined and how its conformational/oligomeric states map to specific trafficking outcomes (lysosomal degradation versus synaptic positioning) remains unresolved.
  • No direct binding interface mapped for TrkB, p75NTR, or IGF2R
  • Functional role of monomer versus dimer conformations in cargo sorting untested
  • Mechanistic bridge between trafficking activity and stem-cell fate undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0038024 cargo receptor activity 4 GO:0060089 molecular transducer activity 2
Localization
GO:0005768 endosome 2 GO:0005794 Golgi apparatus 2 GO:0005886 plasma membrane 2 GO:0005764 lysosome 1 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-9609507 Protein localization 4 R-HSA-162582 Signal Transduction 3 R-HSA-112316 Neuronal System 2 R-HSA-5653656 Vesicle-mediated transport 2
Partners
AP-2IGF2RP75NTRPICK1PSD-95SORCS1TRKB

Evidence

Reading pass · 13 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 SorCS3 (SorCS) was identified as a novel VPS10-domain receptor with an N-terminal VPS10 domain, leucine-rich repeats, a transmembrane domain, and a short intracellular C-terminus containing consensus signals for rapid internalization and putative SH2/SH3 binding motifs, distinct from other VPS10 family members. Molecular cloning, sequence analysis, domain identification Biochemical and biophysical research communications Medium 10600506
2000 An alternatively spliced transcript of SorCS3 was identified that encodes a protein with an identical extracellular/transmembrane region but a completely divergent cytoplasmic tail lacking canonical internalization or sorting signals. RT-PCR, cDNA cloning, sequence analysis of splice variant Biochimica et biophysica acta Medium 10760602
2004 SorCS3 expression in hippocampal neurons is upregulated by kainic acid-induced seizures in an activity-dependent manner that does not require de novo protein synthesis, distinguishing it from the related receptor SorCS1. In situ hybridization, kainic acid seizure model, protein synthesis inhibitor treatment Journal of neurochemistry Medium 15009648
2005 SorCS3 is synthesized as a proprotein and undergoes N-terminal propeptide cleavage in distal Golgi compartments to produce its mature form. The propeptide is not required for normal processing, does not prevent ligand binding, and the receptor predominantly localizes to the plasma membrane with slow internalization and no detectable intracellular trafficking activity. SorCS3 binds nerve growth factor (NGF) as a neurotrophin ligand. Cell transfection, pulse-chase processing assay, ligand-binding assay with purified receptor, subcellular fractionation/localization FEBS letters High 15710408
2013 SORCS3 localizes to the postsynaptic density in hippocampal neurons and is required for NMDA receptor-dependent and -independent forms of long-term depression (LTD). Loss of SORCS3 abrogates LTD and causes faulty localization of the adaptor protein PICK1, suggesting that SORCS3 controls glutamate receptor trafficking at the postsynapse via functional interaction with PICK1. Gene-targeted knockout mice, electrophysiology (LTD recordings), immunofluorescence/postsynaptic density fractionation, targeted proteomics (interaction with PICK1), behavioral fear extinction assay PloS one High 24069373
2014 The SorCS3 cytoplasmic domain targets the receptor to the Golgi apparatus and vesicular structures, and conveys internalization through canonical endocytic motifs in an AP-2-dependent manner. In neurons, SorCS3 protein is localized to vesicles in the soma and dendrites. Chimeric receptor expression in neurons, live-cell imaging/immunofluorescence, AP-2 co-localization, endocytic motif mutagenesis (implied by domain swap experiments) The Journal of comparative neurology Medium 24715575
2017 SorCS3-deficient hippocampal CA1 neurons show reduced basal synaptic transmission (decreased fEPSP slopes), enhanced synaptic facilitation, and reduced synaptic depression during repetitive stimulation, consistent with increased mobility of postsynaptic AMPA receptors. SorCS3 was previously shown to interact with PSD-95 and PICK1 at the postsynaptic density. Electrophysiology on acute brain slices from Sorcs3 knockout mice, immunohistochemistry, patch-clamp recordings Hippocampus High 27935149
2017 SorCS3 extracellular domains form stable homodimers and monomers co-existing in equilibrium. Glycosylation regulates the oligomeric state: enzymatic deglycosylation promotes dimerization of monomers. Membrane-bound dimers were confirmed by co-immunoprecipitation from cell lysate. Biochemical purification, electron microscopy, co-immunoprecipitation, enzymatic deglycosylation Journal of molecular biology High 28827148
2018 SORCS1 and SORCS3 act as intracellular trafficking receptors for tropomyosin-related kinase B (TrkB) in arcuate nucleus neurons to attenuate BDNF signaling. Loss of both receptors results in excessive production of the orexigenic neuropeptide AgRP and a chronic energy excess phenotype. Individual and dual receptor knockout mouse models, biochemical trafficking assays, neuropeptide measurement, metabolic phenotyping EMBO reports Medium 29440124
2022 SorCS3 co-localizes and physically interacts with p75NTR in GBM cells (confirmed by Co-IP and immunofluorescence), promotes endosomal-to-lysosomal trafficking of p75NTR leading to its degradation, thereby suppressing NGF/p75NTR signaling and inhibiting glioma cell invasion and proliferation. Co-immunoprecipitation, immunofluorescence co-localization, lysosomal trafficking assay, p75NTR protein level measurement, invasion/proliferation assays with SorCS3 knockdown/overexpression Cell death & disease Medium 35393432
2022 Cryo-EM structure of full-length human SorCS3 revealed at least three distinct conformations in the apo state: monomer, M-shaped dimer, and N-shaped dimer. Differences between dimer conformations are caused by PKD1-2 domain assembly. Conserved residues GLN198, ARG678, TYR430, GLU1020, and ASP1024 were identified as key for dimerization and protein/polypeptide binding. Cryo-EM structure determination of full-length SorCS3 Biochemical and biophysical research communications High 35940132
2025 SorCS3 enhances endocytosis in adrenocortical carcinoma cells and physically or indirectly interacts with IGF2R (Insulin-like growth factor 2 receptor) as shown by Co-IP. SorCS3 overexpression increases IGF2R protein levels and suppresses PI3K/Akt and MAPK/Erk signaling; blocking endocytosis partially reverses these effects, supporting a receptor trafficking-dependent tumor-suppressive mechanism. Co-immunoprecipitation, immunofluorescence (early endosome co-localization), western blotting for signaling intermediates, endocytosis blocking experiment, overexpression/knockdown functional assays Journal of translational medicine Medium 41121295
2025 Knockout of Sorcs3 in murine embryonic stem cells activates a totipotent-like state associated with activation of the Tfap2c gene and inhibition of TGF-β, PI3K-AKT, and lysosome pathways; deletion of Tfap2c in SKO-ESCs abolished this totipotent potential. CRISPR/Cas9 knockout, single-cell transcriptomics, Tfap2c double-knockout epistasis, blastocyst-like assembly assay, pathway inhibitor validation Advanced science Medium 41178446

Source papers

Stage 0 corpus · 19 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 Sortilin-related receptor SORCS3 is a postsynaptic modulator of synaptic depression and fear extinction. PloS one 72 24069373
1999 Identification and characterization of SorCS, a third member of a novel receptor family. Biochemical and biophysical research communications 67 10600506
2004 The three sorCS genes are differentially expressed and regulated by synaptic activity. Journal of neurochemistry 61 15009648
2018 SORCS1 and SORCS3 control energy balance and orexigenic peptide production. EMBO reports 45 29440124
2005 SorCS3 does not require propeptide cleavage to bind nerve growth factor. FEBS letters 37 15710408
2014 Spatiotemporal expression analysis of the growth factor receptor SorCS3. The Journal of comparative neurology 30 24715575
2020 Non-coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women. Alzheimer's & dementia : the journal of the Alzheimer's Association 27 32966694
2017 The sorting receptor SorCS3 is a stronger regulator of glutamate receptor functions compared to GABAergic mechanisms in the hippocampus. Hippocampus 24 27935149
2017 Hidden Twins: SorCS Neuroreceptors Form Stable Dimers. Journal of molecular biology 16 28827148
2001 Transient expression of SorCS in developing telencephalic and mesencephalic structures of the mouse. Neuroreport 15 11201086
2022 SorCS3 promotes the internalization of p75NTR to inhibit GBM progression. Cell death & disease 14 35393432
2019 Amyloidosis causes downregulation of SorLA, SorCS1 and SorCS3 expression in mice. Biological chemistry 12 31095505
2000 Alternative splicing of murine SorCS leads to two forms of the receptor that differ completely in their cytoplasmic tails. Biochimica et biophysica acta 10 10760602
2015 Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene. Multiple sclerosis (Houndmills, Basingstoke, England) 8 26362888
2023 Independent Associated SNPs at SORCS3 and Its Protein Interactors for Multiple Brain-Related Disorders and Traits. Genes 7 36833409
2018 The SORCS3 gene is mutated in brothers with infantile spasms and intellectual disability. Discovery medicine 7 30586538
2022 Cryo-EM structure studies of the human VPS10 domain-containing receptor SorCS3. Biochemical and biophysical research communications 1 35940132
2025 SorCS3 suppresses adrenocortical carcinoma progression by enhancing IGF2R-mediated endocytic trafficking and signaling attenuation. Journal of translational medicine 0 41121295
2025 Depletion of Sorcs3 Activates Totipotency in Mouse Embryonic Stem Cells by Modulating Key Signaling Pathways. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 41178446

Missed literature

Know a paper Affinage missed for SORCS3? Flag it for the maintainers and the community.

No submissions yet.